Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Updated Organ Response Results of an Open-Label Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis Receiving Anti-Plasma Cell Therapy

Jason Valent, John Silowsky, Michael R. Kurman, Eileen Daniel, Janet Jobes, Mark Harnett, Sherry Fada, Michael Spector, Kathleen Stefunek, Heather Staley, Kristen Schlueter, Christy J. Samaras, Faiz Anwer, Jack Khouri, Jeffrey A. Zonder, Michaela Liedtke, Susan B. Sobolov

Blood (2021) 138 (Supplement 1): 2724.

https://doi.org/10.1182/blood-2021-148905

Published: 2021

Journal Articles

Safety and Tolerability of Cael-101 in Combination with Anti-Plasma Cell Dyscrasia Therapy in Patients with AL Amyloidosis: 1-Year Results from an Open-Label Phase 2 Trial

Jason Valent, Jeffrey A. Zonder, Michaela Liedtke, John Silowsky, Michael R. Kurman, Eileen Daniel, Janet Jobes, Mark Harnett, Jessica Raviwong, Michael Spector, Susan B. Sobolov

Blood (2021) 138 (Supplement 1): 468.

https://doi.org/10.1182/blood-2021-153636

Published: 2021

Journal Articles

Cardiac Amyloid Reaching for Extended Survival (CARES): Study Design of Two Placebo-Controlled, Double-Blind, Randomized, International Phase 3 Trials Assessing Cael-101 in Patients with Mayo Stage Iiia or Stage IIIb AL Amyloidosis

Ashutosh D. Wechalekar, John Silowsky, Eileen Daniel, Mark Harnett, Michael Spector, Susan B. Sobolov, Candida Cristina Quarta, Michael R. Kurman, Mark Tulchinskiy, Amit Bhattacharyya, Michaela Liedtke

Blood (2021) 138 (Supplement 1): 1673.

https://doi.org/10.1182/blood-2021-152488

Published: 2021

Journal Articles

Cael-101 Is Well-Tolerated in AL Amyloidosis Patients Receiving Concomitant Cyclophosphamide-Bortezomib-Dexamethasone (CyborD): A Phase 2 Dose-Finding Study (NCT04304144)

Jason Valent, MD, John Silowsky, RN BSN, Michael R. Kurman, MD, Eileen Daniel, Janet Jobes, Mark Harnett, MS, Margaret Ziola, MD, Jessica Roviwong, Sherry Fada, Michael Spector, BS, Susan B. Sobolov, PhD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-139323

Published: 2020

Journal Articles

Results of a Phase 1, Dose-Escalation Study of FF-10501-01 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Hypomethylating Agent (HMA)-Resistant Myelodysplastic Syndrome (MDS)

Guillermo Garcia-Manero, MD, Michael R. Kurman, MD, Courtney D. DiNardo, MD MSc, Naveen Pemmaraju, MD, Yesid Alvarado, MD, Kiran Naqvi, MD MPH, Farhad Ravandi, MD, Elias J. Jabbour, MD, Ricardo Delumpa, BSN, Timothy Madden, PhD, Gary Maier, PhD, Hiroyuki Iwamura, PhD, Hagop M. Kantarjian, MD

Blood (2018) 132 (Supplement 1): 1438.

https://doi.org/10.1182/blood-2018-99-116613

Published: 2018

Journal Articles

A Prospective, Multicenter, Randomized Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Investigator's Choice in the Treatment of Patients with Relapsed/Refractory Adult T-Cell Leukemia-Lymphoma: Overall Response Rate, Progression-Free Survival, and Overall Survival

Blood (2016) 128 (22): 4159.

https://doi.org/10.1182/blood.V128.22.4159.4159

Published: 2016

Journal Articles

Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma

Madeleine Duvic, Lauren C. Pinter-Brown, Francine M. Foss, Lubomir Sokol, Jeffrey L. Jorgensen, Pramoda Challagundla, Karen M. Dwyer, Xiaoping Zhang, Michael R. Kurman, Rocco Ballerini, Li Liu, Youn H. Kim

Blood (2015) 125 (12): 1883–1889.

https://doi.org/10.1182/blood-2014-09-600924

Published: 2015

Journal Articles

Mature Results of a Phase 1-2 Open-Label, Dose-Escalation Study of Intravenous SNS01-T in Patients (pts) with Relapsed or Refractory B-Cell Malignancies

David S. Siegel, MD PhD, Andrew McDonald, MBChB, Nicolas Novitzky, MD PhD, William Bensinger, Michael Craig, MD, Frits van Rhee, MD PhD, Martin Gutierrez, MD, Edward N. Libby, MD, John Thompson, Alice S Bexon, MD, Charles Barranco, Catherine A Taylor, Richard Dondero, Leslie J. Browne, PhD, Michael R. Kurman, MD, John A. Lust, MD PhD

Blood (2014) 124 (21): 4464.

https://doi.org/10.1182/blood.V124.21.4464.4464

Published: 2014

Journal Articles

Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of a Novel, First-in-Class Modulator of Eukaryotic Translation Initiation Factor 5A (eIF5A) in Patients (pts) with Relapsed or Refractory B-Cell Malignancies: Data from a Phase 1-2 Study

Alice S Bexon, MD, Michael Craig, MD, David S. Siegel, MD PhD, William Bensinger, Nicolas Novitzky, MD PhD, Andrew McDonald, MBChB, Martin Gutierrez, MD, Edward N. Libby, MD, Frits van Rhee, MD PhD, Jeremy Heidel, PhD, John Thompson, Charles Barranco, Catherine A Taylor, Kathleen A. Donovan, PhD, Laurie L. Moon-Tasson, BA, Leslie J. Browne, PhD, Michael R. Kurman, MD, John A. Lust, MD PhD, Richard Dondero

Blood (2014) 124 (21): 2121.

https://doi.org/10.1182/blood.V124.21.2121.2121

Published: 2014

Journal Articles

A Phase 1/2 Study Of KW-2478, An Hsp 90 Inhibitor, In Combination With Bortezomib (BTZ) In Patients (Pts) With Relapsed/Refractory (R/R) Multiple Myeloma (MM)

Cavanagh Jamie, MD, Honorata Giongco Baylon, MD, Priscilla B. Caguioa, MD, Faith E. Davies, MD, Mecide Gharibo, MD, Shiro Akinaga, PhD, Michael R. Kurman, MD, Barbara A. Novak, BS, Kwee L. Yong, PhD

Blood (2013) 122 (21): 1967.

https://doi.org/10.1182/blood.V122.21.1967.1967

Published: 2013

NARROW

Updated Organ Response Results of an Open-Label Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis Receiving Anti-Plasma Cell Therapy

Safety and Tolerability of Cael-101 in Combination with Anti-Plasma Cell Dyscrasia Therapy in Patients with AL Amyloidosis: 1-Year Results from an Open-Label Phase 2 Trial

Cardiac Amyloid Reaching for Extended Survival (CARES): Study Design of Two Placebo-Controlled, Double-Blind, Randomized, International Phase 3 Trials Assessing Cael-101 in Patients with Mayo Stage Iiia or Stage IIIb AL Amyloidosis

Cael-101 Is Well-Tolerated in AL Amyloidosis Patients Receiving Concomitant Cyclophosphamide-Bortezomib-Dexamethasone (CyborD): A Phase 2 Dose-Finding Study (NCT04304144)

Results of a Phase 1, Dose-Escalation Study of FF-10501-01 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Hypomethylating Agent (HMA)-Resistant Myelodysplastic Syndrome (MDS)

A Prospective, Multicenter, Randomized Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Investigator's Choice in the Treatment of Patients with Relapsed/Refractory Adult T-Cell Leukemia-Lymphoma: Overall Response Rate, Progression-Free Survival, and Overall Survival

Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma

Mature Results of a Phase 1-2 Open-Label, Dose-Escalation Study of Intravenous SNS01-T in Patients (pts) with Relapsed or Refractory B-Cell Malignancies

Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of a Novel, First-in-Class Modulator of Eukaryotic Translation Initiation Factor 5A (eIF5A) in Patients (pts) with Relapsed or Refractory B-Cell Malignancies: Data from a Phase 1-2 Study

A Phase 1/2 Study Of KW-2478, An Hsp 90 Inhibitor, In Combination With Bortezomib (BTZ) In Patients (Pts) With Relapsed/Refractory (R/R) Multiple Myeloma (MM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only